Esperion Q2 Retail Prescription Equivalents Grew 26% Y/Y; Q2 New to Brand Prescriptions Grew 28% Q/Q
Portfolio Pulse from Benzinga Newsdesk
Esperion Therapeutics, Inc. (ESPR) reported a 26% year-over-year growth in Q2 retail prescription equivalents and a 28% quarter-over-quarter growth in Q2 new to brand prescriptions.

August 01, 2023 | 10:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Esperion's Q2 results show strong growth in retail prescription equivalents and new to brand prescriptions, indicating a positive market response to its products.
Esperion's reported growth in Q2 retail prescription equivalents and new to brand prescriptions indicates a strong market response to its products. This could potentially lead to increased revenues and profitability, which would likely have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100